1 / 2

Adjuvant Endometrial Cancer Trial Mansoor@rh.regionh.dk

Five phase 3 trials will collaborate internationally to answer 4 major questions in the management of endometrial cancer: Does proper lymphadenectomy improve survival? LYTEC Trial & AGO-ECLAT trial Is there a need for adjuvant chemotherapy in node negative high-risk early stage patients?

ezekiel-phelps
Download Presentation

Adjuvant Endometrial Cancer Trial Mansoor@rh.regionh.dk

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Five phase 3 trials will collaborate internationally to answer 4 major questions in the management of endometrial cancer: • Does proper lymphadenectomy improve survival? • LYTEC Trial & AGO-ECLAT trial • Is there a need for adjuvant chemotherapy in node negative • high-risk early stage patients? • ENGOT-EN2-DGCG trial • Is adjuvant chemo followed by RT better than chemo alone • in high-risk nodal status unknown early stage or stage 3 patients? • NSGO trial • Can combination of standard chemotherapy with targeted therapy compared to combination chemotherapy alone improve disease control rate of advanced or chemo-naïve relapsed endometrial cancer? AGO/NOGGO trial Adjuvant Endometrial Cancer Trial Mansoor@rh.regionh.dk

  2. ENGOT-NESTEC:NEtwork STudy in Endometrial Cancer under the ENGOT umbrella and in cooperation with the Mayo clinic. Clinically presumed: FIGO IB-II any histo type, FIGO I A G3 endometroid, FIGO IA/B histo type II Mayo trial (Dowdy, Mariani) AGO ECLAT trial (Emons) R R NSGO trial (Hogberg) surgery R AGO/NOGGO trial (Sehouli) R DGCG trial (Mirza) No bulky LN Bulky LN FIGO III not Ro and pos. LN or cytology only; FIGO IV Recurrent FIGO I/II In OP LNE R N- N+ + extra LN disease R LNE* no LNE without extra LN disease N- N+ Standard arm: Carbo-paclitaxel + Placebo Experim. arm: Carbo-paclitaxel + mTOR inhibitor R Chemo 1 Carbo-paclitaxel R Chemo +. Radiotherapy Chemo 1 Carbo-paclitaxel observation

More Related